Alzheimer's Association International
Conference includes oral session on PMN310 for Alzheimer's disease
and poster presentation on ALS
TORONTO and CAMBRIDGE, MA, July 18,
2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN)
(OTCQB: ARFXF), a biotechnology company focused on the discovery
and development of antibody therapeutics targeting toxic oligomers
implicated in the development of neurodegenerative diseases,
presented data today for its lead clinical candidate, PMN310 for
Alzheimer's disease, at the annual Alzheimer's Association
International Conference® (AAIC) in Los Angeles. In an oral presentation, Chief
Development Officer Dr. Johanne
Kaplan highlighted the therapeutic potential of PMN310
against the toxic oligomer form of amyloid beta (AßO), a root cause
of Alzheimer's disease. The presentation is now available at
www.promisneurosciences.com. Additionally, Chief Scientific Officer
Dr. Neil Cashman presented data
pertaining to the company's preclinical development program
selectively targeting toxic forms of TDP43 for amyotrophic lateral
sclerosis (ALS) and frontotemporal dementia (FTD).
In today's oral session, Dr. Johanne
Kaplan demonstrated PMN310's ability to:
- Inhibit both the spread and toxicity of AßOs in vitro;
- Prevent AßO-induced loss of memory formation in vivo;
- Reduce both synaptic loss and inflammation in vivo; and,
- Compare favorably with other Aß-directed antibodies, showing a
lack of adverse event-associated binding to Aß deposits in AD
brains, and greater selective binding to AßO-enriched AD brain
fractions that contain Aß neurotoxic species.
On Wednesday, July 17, Dr.
Neil Cashman delivered data from
ProMIS' preclinical program for ALS. Dr. Cashman's poster
presentation demonstrated the role of toxic, misfolded TDP43 as a
root cause of neurodegenerative diseases such as ALS and FTD.
Commenting on this year's conference, Dr. Kaplan shared: "This
year's gathering was arguably one of the most significant as the
research community pivots from a year of discouragement and failure
toward hope. New, incredibly promising therapy development efforts
are underway to target the correct, toxic form of amyloid beta,
advance new biomarkers that can better identify promising therapy
candidates early and mature understanding of new, emerging targets
such as tau and sources of neuroinflammation. With nearly three
decades of hard lessons under our belt, it is wonderful to be a
part of the new, shared momentum and excitement around the path
ahead."
AAIC® is the largest, most influential international
meeting focused on advancing dementia science. The 2019 conference
ended today in Los Angeles,
California. For information on data presented, please visit
www.alz.org/aaic.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines - ProMIS and Collective Coordinates - to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn and listen to the podcast, Saving
Minds, at iTunes or Spotify.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-highlights-data-for-pmn310-at-aaic-2019-300887078.html
SOURCE ProMIS Neurosciences Inc.